Pfizer Boosts Profit Outlook as Battle for Obesity Startup Grows

Pfizer Inc. raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales growth that’s driving its battle for the obesity startup Metsera Inc.

The drugmaker’s adjusted earnings for the year will be $3 a share to $3.15 a share, Pfizer said Tuesday, up from an earlier range that topped out at $3.10 a share, as it continues to slash costs. The company didn’t increase its annual sales expectations of $61 billion to $64 billion, the midpoint of which shows sales growth declining this year from last.